These findings open the door to therapeutic exploration: a cell-penetrant pre-SET–derived peptide (residues 881–893) offers a potential strategy to competitively disrupt the CtBP2–G9a complex, restore PTEN expression, and reduce CRC growth, warranting further investigation as a selective epigenetic intervention. This evidence concerns the gene PTEN and colorectal carcinoma.